{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:20Z","timestamp":1793155820927,"version":"4.5.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-interleukin (IL)-17 biological agents (BAs) have significant efficacy in the treatment of psoriasis and psoriatic arthritis; however, adverse events (AEs) are common, and their safety has not been systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The purpose of this systematic review and meta-analysis was to summarize the number and corresponding rates of AEs caused by anti-IL-17 BAs in patients with psoriasis and psoriatic arthritis to improve clinical decision-making regarding their use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PubMed, Embase, Cochrane Library, and Web of Science databases were independently searched by three authors for articles on the treatment of psoriasis with anti-IL-17 BAs that were published before March 1, 2022, and included at least one AE. Dichotomous variables and 95% confidence intervals (CI) were analyzed using R software (version 4.1.3) and the Meta and Metafor software packages. Funnel plots and meta-regression were used to test for the risk of bias,\n                      <jats:italic>\n                        I\n                        <jats:sup>2<\/jats:sup>\n                      <\/jats:italic>\n                      was used to assess the magnitude of heterogeneity, and subgroup analysis was used to reduce heterogeneity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 57 studies involving 28,424 patients with psoriasis treated with anti-IL-17 BAs were included in the meta-analysis. Subgroup analysis showed that anti-IL-17A (73.48%) and anti-IL-17A\/F (73.12%) BAs were more likely to cause AEs than anti-IL-17R BAs (65.66%). The incidence of AEs was as high as 72.70% with treatment durations longer than one year, and long-term use of medication had the potential to lead to mental disorders. Infection (33.16%), nasopharyngitis (13.74%), and injection site reactions (8.28%) were the most common AEs. Anti-IL-17 BAs were most likely to cause type \u03b1 (33.52%) AEs. Type \u03b4 AEs (1.01%) were rarely observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anti-IL-17 BAs used for the treatment of psoriasis and psoriatic arthritis caused a series of AEs, but the symptoms were generally mild.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.993057","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:34:20Z","timestamp":1675125260000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review"],"prefix":"10.3389","volume":"14","author":[{"given":"Jiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokgyeong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naixuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jdv.14460","article-title":"Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression","volume":"31","author":"Koo","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.jtauto.2021.100104","article-title":"Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases","volume":"4","author":"Akiyama","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15252","article-title":"Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of psoriasis and psoriatic arthritis (NORPAPP)","volume":"33","author":"Tveit","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670398","article-title":"Adverse events associated with anti-IL-23 agents: Clinical evidence and possible mechanisms","volume":"12","author":"Ru","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13222","article-title":"Use of biologics for psoriasis in central and Eastern European countries","volume":"29","author":"Rencz","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14225","article-title":"Assessment of medication adherence and treatment satisfaction in Japanese patients with psoriasis of various severities","volume":"45","author":"Ichiyama","year":"2018","journal-title":"J Dermatol"},{"key":"B9","year":"2017"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0579-y","article-title":"Ixekizumab: First global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.015","article-title":"Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab","volume":"82","author":"Blauvelt","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S267405","article-title":"An overview of bimekizumab for the treatment of psoriatic arthritis: The evidence so far","volume":"15","author":"Oliveira","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.06.024","article-title":"The complexity of adverse side-effects to biological agents","volume":"7","author":"Aubin","year":"2013","journal-title":"J Crohns Colitis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217372","article-title":"Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheumatic Dis."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.066","article-title":"Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study","volume":"80","author":"Mrowietz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez684","article-title":"Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)","volume":"59","author":"Chandran","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-Severe plaque psoriasis (VIP-s)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study","volume":"77","author":"Bagel","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14761","article-title":"Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study","volume":"46","author":"Okubo","year":"2019","journal-title":"J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13927","article-title":"Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)","volume":"44","author":"Imafuku","year":"2017","journal-title":"J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18384","article-title":"A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13900","article-title":"Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study","volume":"44","author":"Wu","year":"2017","journal-title":"J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial","volume":"76","author":"Gottlieb","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","article-title":"Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-s, a phase 3 study","volume":"80","author":"Paul","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12668","article-title":"Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study","volume":"41","author":"Ohtsuki","year":"2014","journal-title":"J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2017.02.005","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study","volume":"108","author":"Valenzuela","year":"2017","journal-title":"Actas Dermosifiliogr."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.032","article-title":"Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study","volume":"79","author":"Leonardi","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15707","article-title":"Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14163","article-title":"Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis","volume":"31","author":"Blauvelt","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-Targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key182","article-title":"Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: Week 52 results from SPIRIT-P2","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0520-z","article-title":"Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: A pooled analysis of phase III studies","volume":"35","author":"K\u00f6rber","year":"2018","journal-title":"Drugs Aging."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"New Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.048","article-title":"A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis","volume":"71","author":"Gordon","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"Br J Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-Severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16558","article-title":"Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)","volume":"35","author":"Bagel","year":"2021","journal-title":"J Eur Acad Dermatol Venereol. JEADV."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15921","article-title":"Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study","volume":"34","author":"Lebwohl","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and safety of ixekizumab through 5 years in moderate-to-Severe psoriasis: Long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheumatic Dis."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab628","article-title":"Response to secukinumab on synovitis using power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE","volume":"61","author":"D'Agostino","year":"2021","journal-title":"Rheumatol (Oxford England)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30036-9","article-title":"Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study","volume":"2","author":"McInnes","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15733","article-title":"Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study","volume":"48","author":"Seo","year":"2021","journal-title":"J Dermatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study","volume":"82","author":"Nakagawa","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16932","article-title":"A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)","volume":"35","author":"Pinter","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheumatic Dis."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study","volume":"83","author":"Blauvelt","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jaad.2019.03.056","article-title":"A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A\/F nanobody, in moderate-to-severe psoriasis","volume":"81","author":"Svecova","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16072","article-title":"Uncovering the unmet needs among psoriasis patients in the Asia-pacific region","volume":"48","author":"Tada","year":"2021","journal-title":"J Dermatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.35541\/cjd.20190847","article-title":"Guideline for the diagnosis and treatment of psoriasis in China (2018 complete edition)","volume":"52","year":"2019","journal-title":"Chin J Dermatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00472-x","article-title":"Two-year US pharmacovigilance report on brodalumab","volume":"11","author":"Lebwohl","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"Cd008794","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: a network meta-analysis and cochrane overview","volume":"2011","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181312","article-title":"Liver abnormalities in patients with psoriatic arthritis","volume":"47","author":"Pakchotanon","year":"2020","journal-title":"J Rheumatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13075-017-1482-y","article-title":"The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs","volume":"19","author":"Cho","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141210","article-title":"Longterm safety of tocilizumab: Results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.993057\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:34:25Z","timestamp":1675125265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.993057\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2023.993057"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.993057","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]},"article-number":"993057"}}